1-10 of 10
Roger B. Cohen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer

Charu Aggarwal, Jeffrey C. Thompson, Austin L. Chien, Katie J. Quinn, Wei-Ting Hwang, Taylor A. Black, Stephanie S. Yee, Theresa E. Christensen, Michael J. LaRiviere, Benjamin A. Silva, Kimberly C. Banks, Rebecca J. Nagy, Elena Helman, Abigail T. Berman, Christine A. Ciunci, Aditi P. Singh, Jeffrey S. Wasser, Joshua M. Bauml, Corey J. Langer, Roger B. Cohen, Erica L. Carpenter
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (10): 2354–2361.
https://doi.org/10.1158/1078-0432.CCR-19-3663
Published: 15 May 2020
View articletitled, Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer
Open the PDF for Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer

Charu Aggarwal, Roger B. Cohen, Matthew P. Morrow, Kimberly A. Kraynyak, Albert J. Sylvester, Dawson M. Knoblock, Joshua M. Bauml, Gregory S. Weinstein, Alexander Lin, Jean Boyer, Lindsay Sakata, Sophie Tan, Aubrey Anton, Kelsie Dickerson, Drishty Mangrolia, Russell Vang, Michael Dallas, Sandra Oyola, Susan Duff, Mark Esser, Rakesh Kumar, David Weiner, Ildiko Csiki, Mark L. Bagarazzi
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (1): 110–124.
https://doi.org/10.1158/1078-0432.CCR-18-1763
Published: 03 January 2019
View articletitled, Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer
Open the PDF for Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer in another window
Includes: Supplementary data
Journal Articles

Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Jeffrey C. Thompson, Stephanie S. Yee, Andrea B. Troxel, Samantha L. Savitch, Ryan Fan, David Balli, David B. Lieberman, Jennifer D. Morrissette, Tracey L. Evans, Joshua Bauml, Charu Aggarwal, John A. Kosteva, Evan Alley, Christine Ciunci, Roger B. Cohen, Stephen Bagley, Susan Stonehouse-Lee, Victoria E. Sherry, Elizabeth Gilbert, Corey Langer, Anil Vachani, Erica L. Carpenter
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (23): 5772–5782.
https://doi.org/10.1158/1078-0432.CCR-16-1231
Published: 30 November 2016
View articletitled, Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA
Open the PDF for Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors

Laura W. Goff, Roger B. Cohen, Jordan D. Berlin, Filippo G. de Braud, Andrej Lyshchik, Cristina Noberasco, Francesco Bertolini, Marina Carpentieri, Corrado Gallo Stampino, Antonello Abbattista, Erjan Wang, Hossein Borghaei
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (9): 2146–2154.
https://doi.org/10.1158/1078-0432.CCR-15-1622
Published: 01 May 2016
View articletitled, A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors
Open the PDF for A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors

John Sarantopoulos, Geoffrey I. Shapiro, Roger B. Cohen, Jeffrey W. Clark, John S. Kauh, Glen J. Weiss, James M. Cleary, Devalingam Mahalingam, Michael D. Pickard, Hélène M. Faessel, Allison J. Berger, Kristine Burke, George Mulligan, Bruce J. Dezube, R. Donald Harvey
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (4): 847–857.
https://doi.org/10.1158/1078-0432.CCR-15-1338
Published: 14 February 2016
View articletitled, Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors
Open the PDF for Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations

E. Claire Dees, Roger B. Cohen, Margaret von Mehren, Thomas E. Stinchcombe, Hua Liu, Karthik Venkatakrishnan, Mark Manfredi, Howard Fingert, Howard A. Burris, III, Jeffrey R. Infante
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (17): 4775–4784.
https://doi.org/10.1158/1078-0432.CCR-12-0589
Published: 30 August 2012
View articletitled, Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations
Open the PDF for Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations in another window
Includes: Supplementary data
Journal Articles

Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements

D. Neil Hayes, Amy S. Lucas, Tawee Tanvetyanon, Monika K. Krzyzanowska, Christine H. Chung, Barbara A. Murphy, Jill Gilbert, Ranee Mehra, Dominic T. Moore, Arif Sheikh, Janelle Hoskins, Michele C. Hayward, Ni Zhao, Wendi O'Connor, Karen E. Weck, Roger B. Cohen, Ezra E.W. Cohen
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (7): 2056–2065.
https://doi.org/10.1158/1078-0432.CCR-11-0563
Published: 01 April 2012
View articletitled, Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements
Open the PDF for Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements in another window
Includes: Supplementary data
Journal Articles

A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer

Eric B. Haura, Alejandro D. Ricart, Timothy G. Larson, Philip J. Stella, Lyudmila Bazhenova, Vincent A. Miller, Roger B. Cohen, Peter D. Eisenberg, Paulina Selaru, Keith D. Wilner, Shirish M. Gadgeel
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (8): 2450–2457.
https://doi.org/10.1158/1078-0432.CCR-09-1920
Published: 14 April 2010
View articletitled, A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer
Open the PDF for A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer in another window
Journal Articles

Phase 1 Experience with an Anti-Glycotope Monoclonal Antibody, RAV12, in Recurrent Adenocarcinoma

Howard A. Burris, III, Lee S. Rosen, Caio M. Rocha-Lima, John Marshall, Suzanne Jones, Roger B. Cohen, Lori A. Kunkel, Deryk Loo, Jan Baughman, Stanford J. Stewart, Nancy Lewis
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (5): 1673–1681.
https://doi.org/10.1158/1078-0432.CCR-09-2263
Published: 28 February 2010
View articletitled, Phase 1 Experience with an Anti-Glycotope Monoclonal Antibody, RAV12, in Recurrent Adenocarcinoma
Open the PDF for Phase 1 Experience with an Anti-Glycotope Monoclonal Antibody, RAV12, in Recurrent Adenocarcinoma in another window
Journal Articles

A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors

Roger B. Cohen, Suzanne F. Jones, Charu Aggarwal, Margaret von Mehren, Jonathan Cheng, David R. Spigel, F. Anthony Greco, Mariangela Mariani, Maurizio Rocchetti, Roberta Ceruti, Silvia Comis, Bernard Laffranchi, Jurgen Moll, Howard A. Burris
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (21): 6694–6701.
https://doi.org/10.1158/1078-0432.CCR-09-1445
Published: 02 November 2009
View articletitled, A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors
Open the PDF for A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data